Key regions: Germany, United States, India, Japan, United Kingdom
The Anti-Rheumatic Drugs market in Bulgaria has been experiencing steady growth in recent years.
Customer preferences: Patients suffering from rheumatoid arthritis and other rheumatic diseases in Bulgaria prefer to use biologic drugs over conventional drugs due to their higher efficacy and lower side effects. This preference is in line with the global trend in the Anti-Rheumatic Drugs market, where biologics are becoming more popular due to their targeted approach and better outcomes.
Trends in the market: The Anti-Rheumatic Drugs market in Bulgaria has been growing steadily due to the increasing prevalence of rheumatic diseases in the country. The aging population and changing lifestyles have contributed to the rising incidence of such diseases. Additionally, the growing awareness among patients and healthcare professionals about the benefits of early diagnosis and treatment has also boosted the demand for Anti-Rheumatic Drugs.
Local special circumstances: Bulgaria is one of the countries with the highest prevalence of rheumatoid arthritis in Europe. The disease affects approximately 1% of the population, with women being more affected than men. The high prevalence of the disease has led to a significant burden on the healthcare system, and the government has taken steps to improve access to treatment for patients.
Underlying macroeconomic factors: The Bulgarian economy has been growing steadily in recent years, and this has contributed to the growth of the Anti-Rheumatic Drugs market. The increasing disposable income of the population has led to a higher demand for healthcare services, including Anti-Rheumatic Drugs. Additionally, the government has been investing in the healthcare sector, which has led to the development of better infrastructure and facilities for patients. These factors have created a conducive environment for the growth of the Anti-Rheumatic Drugs market in Bulgaria.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
